Product Description
Mechanisms of Action: Cytokine Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Belgium | Bosnia | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Ecuador | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Mexico | Morocco | New Zealand | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: POLYSAN Scientific & Technological Pharmaceutical Company
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Kazakhstan, Russia
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Cholestasis, Intrahepatic|Craniocerebral Trauma|Head Injuries, Closed|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
CTF-III-SR-2022 | P3 |
Recruiting |
Stroke |
2024-12-31 |
|
MITRA | P3 |
Completed |
Craniocerebral Trauma|Head Injuries, Closed |
2024-05-07 |